Bentlee Rundell, APRN
Family · Fort Smith, ARNPI 1538649231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 639 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.5% of the total. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 639 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$818
- Pfizer$715
- GSK$697
- Amgen$617
- plus $3K from 32 others
What the payments were for
- Food & beverage$9,84699%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 172 | $2,431 |
| Novo Nordisk | 65 | $1,340 |
| AstraZeneca | 33 | $818 |
| Pfizer | 67 | $715 |
| GSK | 51 | $697 |
| Amgen(2 entities) | 40 | $617 |
| Bayer | 23 | $469 |
| Lilly USA, LLC | 33 | $406 |
| Boehringer Ingelheim | 18 | $287 |
| Amarin Pharma, Inc. | 13 | $248 |
| Otsuka America Pharmaceutical, Inc. | 12 | $222 |
| Sanofi-aventis U.S. LLC | 9 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $158 |
| Johnson & Johnson | 8 | $125 |
| Biohaven Pharmaceuticals, Inc. | 11 | $124 |
| Abbott | 6 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $90 |
| Merck | 6 | $83 |
| Astellas Pharma US Inc | 5 | $76 |
| Corium, LLC | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Averitas Pharma Inc. | 2 | $71 |
| Esperion Therapeutics, Inc. | 5 | $64 |
| Exact Sciences | 3 | $47 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Dexcom, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Dynavax Technologies Corporation | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Boston Scientific | 2 | $30 |
| Novartis | 2 | $29 |
| Lundbeck LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,943 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $79,241 |
| JardianceEmpagliflozin | 23 | $35,003 |
| OzempicSemaglutide | 17 | $30,063 |
| TrulicityDulaglutide | 22 | $27,218 |
| RexultiBrexpiprazole | 17 | $26,805 |
| FarxigaDapagliflozin Propanediol | 23 | $21,110 |
| MyrbetriqMirabegron | 15 | $16,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,818 |
| EliquisApixaban | 16 | $15,327 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,779 |
| Gabapentin | 157 | $2,404 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,376 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,776 |
| Bupropion XlBupropion Hcl | 72 | $1,673 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $406 | $106,45873 claims |
| Boehringer IngelheimJardiance | $287 | $35,00323 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $818 | $30,88938 claims |
| Novo NordiskOzempic | $1,340 | $30,06317 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $222 | $26,80517 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $16,39515 claims |
| GSKTrelegy Ellipta | $697 | $15,81824 claims |
| PfizerEliquis | $715 | $15,32716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Fort Smith
- Nina CopelandFort Smith$207K
- Amanda DavisFort Smith$46K
- Scarlett BoneFort Smith$16K
- Nathan WilliamsonFort Smith$15K
- Yong OunpraseuthFort Smith$14K
- Karen WilliamsFort Smith$11K
- Nycole OliverFort Smith$10K
- Nata MatthewsFort Smith$10K
- Emily ChristensenFort Smith$9K
- Karen ThriftFort Smith$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.